Ordinary vaccines cause inactive or weak germs, when injected into the body, stimulate a immune response that can later protect against living diseases.
The night before dark, he says, is dark before night. It is certainly dark now. The more infectious strains of SARS-CoV-2 from Britain and South Africa would make the epidemic worse before vaccination.
But take another look at these new vaccines and then think about the coming dawn – not just its first rays in the coming months, but also the bright lights of years and decades to come. It seems more plausible that the weapons we use to defeat Covid-19 can also defeat Grim Harvesters, including cancer, which kills about 10 million people a year.
The most promising Covid vaccine uses a nucleic acid called RNA or mRNA. One vaccine is from German firm Biotech SE and its US partner Pfizer Inc. The second American company to come from is Modern. The other is from Kurevak NV, located in Germany
Ordinary vaccines cause inactivity or weakened germs that, when injected into the body, stimulate an immune response that can prevent later living diseases. But the process of making such a vaccine requires different types of chemicals and cell cultures. It takes time and provides opportunities for pollution.
mRNA vaccines do not have this problem. They instruct the body to make invasive proteins – in this case, which encode viral RNAs of SARS-COV-2. The immune system then resides in this antigen, on which day the same protein appears to be associated with the coronovirus.
It has a great promise of mRNA: it can tell our cells what we want It contains antigens for many other diseases besides Covid-19
In its day-to-day work, mRNA directs from its molecular cousin, the DNA in our cell nucleus. Genome stretches are imitated and the mRNA reaches the cytoplasm, where small cellular plants called ribosomes use information to process protein.
BioNTech and Moderna Shortcuts leave this process entirely in the nucleus with DNA. Instead, they first find out what protein they need – for example, a spike on the coat around the germ. They then look at the sequence of amino acids that make up this protein This gives them the correct instructions that should give the mRNA
The process can be relatively rapid, which took less than a year to produce, which is an unprecedented pace. It is also genetically safe – mRNA cannot return to the nucleus and suddenly inserts genes into our DNA.
In the 1st century s, researchers created a hunch that you could use this queue to deal with all kinds of disabilities. But always in science, you need a lot of money, time and patience to solve all the mediating problems. After a decade of enthusiasm, the mRNA academy became essential in the 1990s Progress seemed to be stopping. The main obstacle is that injecting mRNA into animals often results in fatal inflammation.
Enter Catalin Carico – A Hungarian scientist who went to the United States in the 1980s and devoted his entire career to mRNA. In the 1990s, he lost money, became delinquent, lost his salary, and faced other difficulties. But he grabbed it by the jaw. And then, after being diagnosed with cancer himself, he achieved remarkable success.
In the 2000s, he and his research colleagues found that changing one of the “letters” of the mRNA “uridine” would not cause inflammation without addressing symptoms. Rats survived.
His study was read by Stanford University scientist Derek Rossi, who later co-founded Modern. It attracted the attention of Ukur Sahin and Ozlem Tursi, two oncologists who co-founded Husband and Wife and Bionotech. He licensed and leased Carrico’s technology. From the beginning, he was interested in cancer treatment
Today’s weapon against cancer will one day look like the Flint Curry motif in the operating room. To kill a malignant tumor, you usually irradiate it with radiation or chemicals, damaging other tissues in the process.
Sahin and Tulsi have found that the best way to deal with cancer is to use each tumor in a genetically unique manner and to train the individual patient’s immune system against that particular enemy. One of the best things for mRNA is finding antigens, getting fingerprints, reversing defectors and reversing cellular instructions to make other parts of the body.
Take a look at modern and bio-tech pipelines, including breast, prostate, skin, pancreas, brain, lungs, and other tissues for the treatment of zika and rebabe from influenza. Hope is looking good
In short, progress has been slow. Part of the explanation given by Sahin and Tulsi is that investors in the sector have to invest and then wait for over a decade, first for testing, then for regulatory approval. In the past, very few people were in the mood
covid-19, fingers crossed, all of these processes can be turbo-charged. Epidemic vaccines have a major impact on specific evidence of mRNA vaccines and their concept. The Nobel Prize for cargo has been expressed dissatisfaction. From now on, mRNAs will have no problem receiving funding, attention or incentives from investors, regulators and policy makers.
This does not mean that the final stretch will be easy but in this dark hour, basking is allowed in the morning light.